Bioceres Gets Nasdaq Reprieve: Transfer to Capital Market and 180-Day Extension to Regain $1 Bid
BIOX sits 30% above its 52-week low of $0.301 on elevated volume (2.9× avg).
Summary
Bioceres received a Nasdaq extension until March 15, 2027 to regain the $1.00 minimum bid price, with a transfer to the Capital Market effective September 18. A reverse stock split remains a live option.
Key Events · Legal and Risk Events · BIOX
-
Nasdaq Transfer and Compliance Extension
Nasdaq approved Bioceres' transfer from the Global Market to the Capital Market effective September 18, 2026, and granted an additional 180-day compliance period until March 15, 2027 to regain the $1.00 minimum bid price.
-
Reverse Split on the Table
The company must complete any reverse stock split no later than 10 business days prior to March 15, 2027. At the current $0.392 share price, a reverse split would be required to reach $1.00, representing significant dilution risk for existing holders.
-
Financial Distress Context
The extension comes amid a $31.8M Q4 net loss from continuing operations, $213.6M in net financial debt, and $118.6M in accelerated secured notes subject to ongoing creditor litigation.
-
Delisting Risk Remains
If compliance is not demonstrated by March 15, 2027, Nasdaq will issue a delisting notice, at which point Bioceres may appeal to a Hearings Panel. There is no assurance the company will regain compliance.
Analysis · BIOX · Industrial Applications And Services
Bioceres avoided immediate delisting after failing to regain the $1.00 minimum bid price by the September 14 deadline. Nasdaq approved a transfer to the Capital Market effective September 18 and granted an additional 180 days, until March 15, 2027, to regain compliance. The company has stated it will evaluate a reverse stock split if necessary, which would be highly dilutive to existing holders at the current $0.392 share price. This comes against a backdrop of a $31.8M quarterly net loss, $213.6M in net debt, and an ongoing creditor dispute over $118.6M in accelerated secured notes.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 35.1% of the 1081 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOX was trading at $0.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.6M. The 52-week trading range was $0.30 to $2.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.